MSD Animal Health Announces First WSAVA Michael J. Day Scholarship Recipient
Winning veterinary student sets out to examine canine tick-borne diseases in Nepal
MADISON N.J., February 23, 2023 – MSD Animal Health, a division of Merck & Co., Inc., Rahway, N.J., USA (NYSE:MRK), today announced the inaugural recipient of the World Small Animal Veterinary Association (WSAVA) Michael J. Day Scholarship, Somnath Aryal. Aryal, a Nepalese veterinary student at the Agriculture and Forestry University in Chitwan, was selected as the winner out of the numerous submissions. His winning study proposal will examine the frequency of canine tick-borne diseases in Nepali dog populations, with the goal of improving and promoting the diagnosis and treatment of canine tick-borne diseases in Nepal. As the recipient of this scholarship, Aryal will receive a $15,000 grant provided by MSD Animal Health to fund the study’s research.
“We’re honored to support Somnath’s research goals and his chosen veterinary studies in memory of Michael J. Day,” said Ingrid Deuzeman, director, Global Companion Animal Vaccines Marketing, MSD Animal Health. “So many brilliant minds applied for the WSAVA Michael J. Day Scholarship in its inaugural year, and we’re excited to provide more opportunities such as this to other veterinary students in the future.”
In honor of Emeritus Professor Michael Day, chair of the WSAVA’s Vaccination Guidelines Group (VGG) from 2009 until March 2020, WSAVA created The Michael J. Day Scholarship, which provides a selected recipient with research funding for studies in companion animal infectious diseases, clinical vaccinology, or immunology. The scholarship invited veterinary students studying towards a veterinary degree in an accredited veterinary establishment to apply. The winning study’s results are expected to become available near the end of 2023.
About WSAVA
The WSAVA represents more than 200,000 veterinarians worldwide through its 115 member associations and works to enhance standards of clinical care for companion animals. Its core activities include the development of WSAVA Global Guidelines in key areas of veterinary practice, including pain management, nutrition and vaccination, together with lobbying on important issues affecting companion animal care worldwide.
About MSD Animal Health
At MSD, known as Merck & Co., Inc., Rahway, N.J., USA in the United States and Canada, we are unified around our purpose: We use the power of leading-edge science to save and improve lives around the world. For more than a century, we’ve been at the forefront of research, bringing forward medicines, vaccines and innovative health solutions for the world’s most challenging diseases. MSD Animal Health, a division of Merck & Co., Inc., Rahway, N.J., USA, is the global animal health business of MSD. Through its commitment to The Science of Healthier Animals®, MSD Animal Health offers veterinarians, farmers, pet owners and governments one of the widest ranges of veterinary pharmaceuticals, vaccines and health management solutions and services as well as an extensive suite of connected technology that includes identification, traceability and monitoring products. MSD Animal Health is dedicated to preserving and improving the health, well-being and performance of animals and the people who care for them. It invests extensively in dynamic and comprehensive R&D resources and a modern, global supply chain. MSD Animal Health is present in more than 50 countries, while its products are available in some 150 markets. For more information, visit www.msd-animal-health.com and connect with us on LinkedIn and Twitter.
Forward-Looking Statement of Merck & Co., Inc., Rahway, N.J., USA
This news release of Merck & Co., Inc., Rahway, N.J., USA (the “company”) includes “forward-looking statements” within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. These statements are based upon the current beliefs and expectations of the company’s management and are subject to significant risks and uncertainties. There can be no guarantees with respect to pipeline candidates that the candidates will receive the necessary regulatory approvals or that they will prove to be commercially successful. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements.
Risks and uncertainties include but are not limited to, general industry conditions and competition; general economic factors, including interest rate and currency exchange rate fluctuations; the impact of the global outbreak of novel coronavirus disease (COVID-19); the impact of pharmaceutical industry regulation and health care legislation in the United States and internationally; global trends toward health care cost containment; technological advances, new products and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approval; the company’s ability to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk; dependence on the effectiveness of the company’s patents and other protections for innovative products; and the exposure to litigation, including patent litigation, and/or regulatory actions.
The company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. Additional factors that could cause results to differ materially from those described in the forward-looking statements can be found in the company’s Annual Report on Form 10-K for the year ended December 31, 2021 and the company’s other filings with the Securities and Exchange Commission (SEC) available at the SEC’s Internet site (www.sec.gov).